2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

101. Red Cells and Erythropoiesis, Excluding Iron: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Genetic Disorders, Hemoglobinopathies, Thalassemia, Immunology, Autoimmune Hemolytic Anemia, Infectious Diseases, Myeloid Malignancies, Metabolic Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

1116 Autosomal recessive SPTA1 hereditary spherocytosis (HS): Genotype-phenotype correlations and the case for genetic testing in HS

Clarisse Emily Carcao, N/A, Melanie Kirby, MD2, Diandra Rollan, RN3, Michelle Fantauzzi, RN4, Sheila Butchart, RN5, Camilla Cellarius6, Manuel Carcao, MD7, Jillian Baker, MD8
1 The Hospital for Sick Children, Toronto, Ontario, Canada
2 The Hospital for Sick Children, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
3 The Hospital for Sick Children, Toronto, Ontario, Canada
4 The Hospital for Sick Children, Toronto, Ontario, Canada
5 The Hospital for Sick Children, Toronto, Ontario, Canada
6 The Hospital for Sick Children, Toronto, Ontario, Canada
7 The Hospital for Sick Children, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
8 The Hospital for Sick Children, Toronto, Ontario, Canada, Unity Health (St. Michael’s Hospital), Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada

Background: Hereditary spherocytosis (HS) is the most common inherited red cell membrane disorder, usually caused by autosomal dominant (AD) pathogenic variants in ANK1, SPTB, or SLC4A1 genes. Rarely, HS results from biallelic SPTA1 variants inherited in an autosomal recessive (AR) pattern. SPTA1 encodes α-spectrin, which together with β-spectrin forms the erythrocyte membrane skeleton. Because α-spectrin is normally produced in excess of β-spectrin, SPTA1-associated HS generally requires biallelic pathogenic SPTA1 variants. Disease severity depends on residual α-spectrin expression. Two common hypomorphic alleles, αLEPRA and αLELY, partially preserve α-spectrin expression and modify disease severity. Children with AR SPTA1-HS typically have unaffected heterozygous parents and without genetic testing are likely to be misclassified as having de novo AD HS. Genetic testing is thus essential for prognostication, sibling recurrence risk, and reproductive counselling. Recognition of a misclassified family inspired our institution to adopt routine HS genetic testing and to undertake this retrospective review.

Aim: To characterize the clinical and genetic spectrum of AR SPTA1-associated HS at a single pediatric center and determine the frequency of inheritance pattern misclassification.

Methods: We conducted a retrospective chart review of all patients with genetically confirmed SPTA1-associated HS, followed at The Hospital for Sick Children, Toronto. Family history, clinical characteristics, genotypes, transfusion history, and surgical history were obtained. Laboratory values were collected at baseline, 1-year post-splenectomy, and at the most recent follow-up, through to May 31, 2026. Disease severity was classified using Bolton-Maggs 2011 BJH criteria.

Results: Thirteen patients from 9 unrelated families were identified. In 3 families (33%) the first/only affected child was initially thought to have de novo AD HS and reclassified 5–17 years later, following genetic testing. All patients presented with moderate-to-severe disease.

αLEPRA was the most common pathogenic allele (7/13, 54%). In no patient was αLELY thought to be disease causing. In addition to αLEPRA, eight other pathogenic SPTA1 variants were identified, including six novel variants. Two patients carried homozygous genotypes; αLEPRA/αLEPRA (non-consanguineous parents) and p.Val447Asp/p.Val447Asp (consanguineous parents), the latter having the most severe phenotype.

All patients required at least one transfusion, and 6 (46%) were transfusion-dependent before splenectomy (needing transfusions every 2-8 weeks). Transfusion dependence was less common among patients carrying αLEPRA (1/7, 14%) compared to those without αLEPRA (5/6, 83%).

In the 11 patients with available baseline values, hemoglobin was markedly reduced in all (mean 74.9 g/L, range, 30–103). Reticulocytosis was present in all patients (mean 406 x109/L, range 230-597). Bilirubin was elevated in all 11 patients (mean 53 μmol/L, range, 24–115), with 10 of the total cohort, developing cholelithiasis requiring cholecystectomy (mean age: 7.8 yr).

All 13 patients underwent splenectomy before 11 years of age (mean age: 5 yr). Four underwent total splenectomy (mean age: 3.6 yr). Nine initially underwent partial splenectomy (mean age: 5.6 yr), with 6 subsequently requiring completion splenectomy (mean age: 10.8 yr) for recurrent disease (n=4) or quality-of-life (n=2). At latest follow up post-splenectomy, mean hemoglobin normalized (137.1 g/L), reticulocyte counts remained mildly elevated (mean 175.2 x109/L), and bilirubin levels remained elevated (mean 27.7 umol/L). These findings indicate persistent low-grade hemolysis despite splenectomy.

Conclusions:?Autosomal recessive SPTA1-associated HS is characterized by moderate-to-severe hemolytic anemia, frequent transfusion dependence, and the need for splenectomy in early childhood. In our cohort, we identified six novel pathogenic SPTA1 variants. SPTA1-associated HS caused by the αLEPRA mutation was milder than non-αLEPRA SPTA1-associated HS. One-third of families were initially misclassified as having de novo AD HS, thus delaying accurate recurrence risk assessment and appropriate genetic counselling by up to 17 years. Where available, genetic testing should be incorporated into the diagnostic workup of children with HS born to clinically unaffected parents.

Jillian Baker, MD: No relevant conflicts of interest to declare.